Dernières nouvelles pour Tenable Holdings (NASDAQ:TENB) Stock

Tenable Holdings

Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.

Tenable Holdings Inc

FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) lowers FY2024 sales outlook from $545.65 million-556.56 million to $540.19 million-545.65 million.

News

Guidance

FIGS

FIGS Lowers FY2024 Sales Guidance from $545.65M-556.56M to $540.19M-545.65M

ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.79) by 26.58 percent.

Earnings

Earnings Beats

ALXO

ALX Oncology Holdings Q3 2024 GAAP EPS $(0.58) Beats $(0.79) Estimate

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.31) by 93.55 percent. The company reported quarterly sales of $56.664 million which missed the analyst consensus estimate of $58.042 million by 2.37 percent. This is a 0.90 percent increase over sales of $56.157 million the same period last year.

Earnings Misses

CYRX

CryoPort Q3 2024 GAAP EPS $(0.02) Beats $(0.31) Estimate, Sales $56.664M Miss $58.042M Estimate

Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 41.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $190.00 thousand which missed the analyst consensus estimate of $2.25 million by 91.56 percent. This is a 81.85 percent decrease over sales of $1.05 million the same period last year.

MVIS

Microvision Q3 EPS $(0.07) Beats $(0.10) Estimate, Sales $190.00K Miss $2.25M Estimate

At current rates, the Company expects negligible year-over-year currency impact on the full year 2024 revenues.
Additionally, Artivion continues to expect adjusted EBITDA growth of between 28% and 34% for the full year 2024 compared to 2023 resulting in an expected range of $69 to $72 million for 2024.

AORT

Artivion Narrows FY24 Revenue Outlook From $388M -$396M To $389M - $396M, Est $391.955M

Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.12 by 8.33 percent. The company reported quarterly sales of $102.638 million which beat the analyst consensus estimate of $102.001 million by 0.62 percent. This is a 20.00 percent increase over sales of $85.532 million the same period last year.

Sprout Social Q3 2024 Adj. EPS $0.13 Beats $0.12 Estimate, Sales $102.638M Beat $102.001M Estimate

W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. The company reported quarterly sales of $121.372 million which missed the analyst consensus estimate of $122.406 million by 0.84 percent. This is a 14.77 percent decrease over sales of $142.411 million the same period last year.

W&T Offshore Q3 2024 Adj. EPS $(0.17) Beats $(0.19) Estimate, Sales $121.372M Miss $122.406M Estimate

Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.37) by 29.73 percent. The company reported quarterly sales of $26.03 million which missed the analyst consensus estimate of $34.37 million by 24.26 percent. This is a 74.03 percent increase over sales of $14.96 million the same period last year.

ACLX

Arcellx Q3 2024 GAAP EPS $(0.48) Misses $(0.37) Estimate, Sales $26.03M Miss $34.37M Estimate

Management

Natural Gas Services Group Announced The Appointment Of Ian Eckert As CFO Effective No Later Than January 5th, 2026. NGS's Current Interim CFO John Bittner Will Continue In that Role Until Mr. Eckert's Start Date

Con Edison CFO Kirk Andrews Says We Are Narrowing And Revising Our 2024 Adjusted EPS Guidance To The Upper Half Of Our Original Range

Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) sees Q4 sales of $40.000 million-45.000 million vs $50.03 million estimate.

CMBM

Cambium Networks Sees Q4 Sales $40.000M-45.000M vs $50.03M Est

SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.03 by 66.67 percent. The company reported quarterly sales of $97.400 million which beat the analyst consensus estimate of $96.647 million by 0.78 percent. This is a 23.73 percent increase over sales of $78.718 million the same period last year.

SEMR

SEMrush Hldgs Q3 2024 GAAP EPS $0.01 Misses $0.03 Estimate, Sales $97.400M Beat $96.647M Estimate

Sandstorm Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) reported quarterly sales of $44.700 which missed the analyst consensus estimate of $44.900 million by 100.00 percent. This is a 100.00 percent decrease over sales of $41.324 million the same period last year.

SAND

Sandstorm Gold Q3 Sales $44.700 Miss $44.900M Estimate

nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 20 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $56.13 million which beat the analyst consensus estimate of $55.27 million by 1.55 percent. This is a 10.85 percent increase over sales of $50.63 million the same period last year.

LASR

nLight Q3 Adj $(0.08), Inline, Sales $56.13M Beat $55.27M Estimate

Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) is looking for Q2 Adj EPS of $0.30-0.40 vs $0.27 analyst estimate. sees sales of $380.000 million-400.000 million vs $354.32 million estimate.

LITE

Lumentum Holdings Sees Q2 Adj EPS $0.30-0.40 vs $0.27 Est; Sees Sales $380.000M-400.000M vs $354.32M Est

Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.62 by 3.7 percent.

Consolidated Edison Q3 2024 Adj. EPS $1.68 Beats $1.62 Estimate

PDF Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDFS#NASDAQ">PDFS</a>) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.20 by 25 percent. The company reported quarterly sales of $46.409 million which beat the analyst consensus estimate of $46.196 million by 0.46 percent. This is a 9.58 percent increase over sales of $42.350 million the same period last year.

PDFS

PDF Solutions Q3 2024 Adj. EPS $0.25 Beats $0.20 Estimate, Sales $46.409M Beat $46.196M Estimate

TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) affirms FY2024 sales outlook from $74.50 million-76.50 million to $74.50 million-76.50 million.

TELA

TELA Bio Affirms FY2024 Sales Guidance from $74.50M-76.50M to $74.50M-76.50M

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) affirms FY2025 Product sales outlook from $450.00 million-475.00 million to $450.00 million-475.00 million.

IOVA

Iovance Biotherapeutics Affirms FY2025 Product Sales Guidance from $450.00M-475.00M to $450.00M-475.00M

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) raises FY2024 sales outlook from $580.00 million-595.00 million to $620.00 million-635.00 million.

COLL

Collegium Pharmaceutical Raises FY2024 Sales Guidance from $580.00M-595.00M to $620.00M-635.00M  VS Est.625.37M

Sees Q4 revenue $229M-$233M, consensus $232.03M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...

Tenable sees Q4 EPS 33c-35c, consensus 32c

Tenable Holdings, Inc. (TENB) Q3 2024 Earnings Call Transcript

Analyst Hamza Fodderwala from Morgan Stanley maintained a Buy rating on Tenable Holdings (TENB – Research Report) and keeping the price target at $...

Tenable Holdings: Strong Performance and Growth Potential Justify Buy Rating

TD Cowen analyst Shaul Eyal reiterated a Buy rating on Tenable Holdings (TENB – Research Report) today and set a price target of $55.00. Shaul Eyal...

Tenable Holdings: Strong Growth Potential and Strategic Expansion Drive Buy Rating

Barclays lowered the firm's price target on Tenable (TENB) to $45 from $49 and keeps an Equal Weight rating on the shares post the Q3 report. Publi...

Tenable price target lowered to $45 from $49 at Barclays

Canaccord Genuity analyst Kingsley Crane has maintained their bullish stance on TENB stock, giving a Buy rating today. Kingsley Crane has given his...

Tenable Holdings: Strong Financial Performance and Strategic Initiatives Drive Buy Rating

Stifel Nicolaus analyst Brad Reback maintained a Buy rating on Tenable Holdings (TENB – Research Report) yesterday and set a price target of $46.00...

Stifel Nicolaus Remains a Buy on Tenable Holdings (TENB)

Truist Financial analyst Joel Fishbein maintained a Buy rating on Tenable Holdings (TENB – Research Report) yesterday and set a price target of $48...

Truist Financial Remains a Buy on Tenable Holdings (TENB)

Robert W. Baird analyst Shrenik Kothari has maintained their bullish stance on TENB stock, giving a Buy rating yesterday. Shrenik Kothari has given...

Tenable Holdings: Strong Revenue Growth and Strategic Partnerships Fuel 'Buy' Rating

Tenable Holdings (TENB) has disclosed a new risk, in the Technology category. Tenable Holdings faces significant risks by incorporating generative ...

Comments

Tenable Holdings

Actualités

Dernières nouvelles pour Tenable Holdings (NASDAQ:TENB) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL